Fig. 2From: Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home settingChange in LDL-C from baseline to 6 weeks in THOMAS-1 and to the mean of weeks 10 and 12 in THOMAS-2. LDL-C was based on calculated values unless calculated LDL-C was <40 mg/dL or triglycerides were >400 mg/dL, in which case the ultracentrifugation LDL-C value from the same blood sample was used instead, if available. AI autoinjector, AMD automated minidoser, LDL-C low-density lipoprotein cholesterol, PFS prefilled syringe, Q2W biweekly (140 mg), QM monthly (420 mg), SE standard error, T-1 THOMAS-1, T-2 THOMAS-2Back to article page